Redwood City, CA; 2/24/20
Amount Funded: $165 Million
Type: Series B
Lead Investor: Softbank Vision Fund
Participating Investor(s): General Catalyst, HBM Healthcare Investments, Khosla Ventures, LightSpeed Venture Partners
Company Description: Karius is a life sciences company focused on generating genomic insights for infectious diseases with a non-invasive blood test that helps clinicians make rapid treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health.
What funding will be used for:
Expand access to proprietary microbial cell-free DNA technology, helping doctors diagnose infectious diseases, broaden clinical development, accelerate technology innovation.
“This transformative round will allow Karius to help more patients faster, fuel the next wave of clinical studies, and accelerate technology innovation. We are humbled to be part of the team that delivered the first clinical applications of microbial cell-free DNA and are excited about what’s ahead for Karius.”
-Mickey Kertesz, CEO, Karius
- Karius reports that its test is being used in over 100 hospitals and health systems nationwide (as of 2/24/20).
Data provided by respective company (unless otherwise noted) and researched by StartupsOne for accuracy.